Trade MiMedx Group Inc - MDXG CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02224 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02224%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00001 %($0.00)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00001%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02224 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00001 %
  ($0.00)

Key Stats

• Prev. Close: 4.67
• Open: 4.6
• 1-Year Change: -31.24%
• Day's Range: 4.4 - 4.61

Trade MiMedx Group Inc - MDXG

About MiMedx Group Inc

MiMedx Group, Inc. is utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing the needs of patients with acute and chronic non-healing wounds, and a late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The Company’s platform technologies include AmnioFix, EpiFix, EpiCord, AmnioCord and AmnioFill. Its AmnioFix and EpiFix are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. The EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. Its AmnioFill is a particulate product comprised of placental connective tissue matrix, derived from the placental disc and placental membranes.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, MiMedx Group Inc revenues increased 4% to $258.6M. Net loss applicable to common stockholders decreased 80% to $16.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investigation, restatement and related decrease of 94% to $3.8M (expense), Loss on extinguishment of debt decrease from $8.2M (expense) to

Equity composition

Common Stock $.001 Par, 03/11, 100M auth., 64,331,910 issd., less 50,000 shs. in Treas. @ $25K. Insiders own approx. 18.35%.